THERAPY DOSSIER · th-e10979efcf2b

TGF-beta1

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Haemorrhage/shock
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27893460 ↗2016Reported benefit

TGF-beta1 modulates microglial phenotype and promotes recovery after intracerebral hemorrhage.

MouseHaemorrhage/shockUnspecifiedAdministered following intracerebral haemorrhage; exact interval not stated in…

Model: Murine intracerebral haemorrhage; model details not specified in the available text

TGF-beta1 treatment after intracerebral haemorrhage reduced microglial Il6 expression and improved functional outcomes in mice. Patients with early increases in plasma TGF-beta1 had better outcomes at 90 days.

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…